Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
NCT00327444 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
- Lead sponsor
- Sanofi
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- October 31, 2009
- Enrollment
- 58 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.